The toxicology studies program for its lead TYK2/JAK1 inhibitor, SDC-1801, are starting. In 2024, SDC-1801 which is a dual inhibitor targeting autoimmune diseases, completed Phase 1 clinical trials in healthy volunteers which demonstrated a favorable safety and pharmacokinetic profile. These toxicology studies are the next key regulatory milestone on the pathway to a Phase 2 development programme. The studies are designed to support longer-term dosing of SDC-1801 and will investigate the gen ....